Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2024 21:50 ET | Source: Belite Bio, Inc

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...
May 13, 2024 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
May 08, 2024 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative...
May 06, 2024 08:15 ET | Source: Belite Bio, Inc

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

Webinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET Discussion will feature Dr. Michel Michaelides, leading expert in the field of inherited eye disease...
May 06, 2024 08:00 ET | Source: Belite Bio, Inc

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

Additional analysis of visual acuity loss, genotypic profiles, and retinal imaging data from a 24-month Phase 2 trial of Tinlarebant in adolescent Stargardt disease patients provides further support...
May 01, 2024 16:15 ET | Source: Belite Bio, Inc

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...
April 25, 2024 19:15 ET | Source: Belite Bio, Inc

Belite Bio Announces $25 Million Registered Direct Offering

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel...
March 22, 2024 08:00 ET | Source: Belite Bio, Inc

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...
March 11, 2024 22:28 ET | Source: Belite Bio, Inc

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
March 11, 2024 21:27 ET | Source: Belite Bio, Inc

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...